Resolution of inflammation after cardiac arrest
Resolution of inflammation after cardiac arrest
批准号:
10566655
负责人:
Edy Yong Kim
金额:
$84.41万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-01-01 至 2027-12-31
关键词:
AddressAgonistAnti-Inflammatory AgentsBioinformaticsBrainBrain InjuriesCardiacCardiopulmonary ResuscitationCause of DeathCellsChestCirculationClinicalCollaborationsCritical CareCryopreservationDataEnrollmentGoalsHeartHeart ArrestHospitalizationImmuneImmune TargetingImmune responseImmune systemImmunologyImmunophenotypingIn VitroInflammationInflammatoryInflammatory ResponseInjuryInterferon Type IIInterleukin-10InterventionMediatingMethodsMonoclonal AntibodiesMusNatural Killer CellsNervous System TraumaNeurologicNeurological outcomeOutcomePathway interactionsPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsProductionReactionRecombinantsResolutionResourcesResuscitationSepsisSiteTestingTherapeuticTherapeutic InterventionTimeValidationbiobankcheckpoint receptorsclinically relevantcohortcytokineimmune checkpointimmune functionimmunoregulationimprovedmonocytemortalitymouse modelmultidisciplinarynectinnovel therapeutic interventionout-of-hospital cardiac arrestpreventprospectiveresponsesingle-cell RNA sequencingsystemic inflammatory responsetherapeutic candidatetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Out of hospital cardiac arrest (OHCA) produces an early systemic inflammatory response associated with
significant neurological injury and mortality. Unlike sepsis, OHCA offers an opportunity to intervene at the
earliest stages of the immune response. However, the immunology of cardiac arrest is understudied. To
address this, we started the multi-center Immunology of Cardiac Arrest Network (I-CAN), a collaboration
applying single-cell approaches to a unique biobank of cryopreserved, viable peripheral blood mononuclear
cells (PBMC) from OHCA patients. Our premise is that cardiac arrest triggers endogenous, compensatory
mechanisms that promote the resolution of inflammation, limit injury and improve survival. Our preliminary
studies identified that monocyte and NK cell states expressing immune checkpoints were expanded in patients
with poor neurological outcomes. Interactome analysis identified cytokines (IFNγ, IL-10) that mediate cross-talk
between Nectin-2+ monocytes and Tim-3+ TIGIT+ NK cells. Subsequent ex vivo studies on PBMC from OHCA
patients demonstrated that Nectin-2 is a brake on production of IFNγ by NK cells. IFNγ-deficient mice in
experimental cardiac arrest and resuscitation had reduced neurological injury and mortality. These findings
suggest our hypothesis that Nectin-2 monocytes are a protective response to ameliorate inflammation and
neurological injury after OHCA. Here, we propose to define the mechanisms that resolve inflammation after
cardiac arrest. In Aim 1, we perform deep immunophenotyping of OHCA patients at single-cell resolution. In
Aim 2, we define the immune checkpoint profile of OHCA and its association with neurological outcomes. We
then define the function of immune checkpoints in OHCA, with a focus on Nectin-2+ monocytes. In Aim 3, we
test targeting of immune checkpoint receptors as a therapeutic strategy in a mouse model of cardiac arrest and
resuscitation. Together, these aims define a new therapeutic approach: augmentation of endogenous,
protective mechanisms to reduce inflammation after cardiac arrest. Further, our multi-center and multi-
disciplinary team in the Immunology of Cardiac Arrest Network (I-CAN) establishes the resource of a two-site
biorepository of clinical cardiac arrest with deep immunophenotyping of the subjects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: